Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | HTR3A | P46098 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 1/20 | 0.45 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575740 | 0.86 | AXL (0.62) | MAP4K1BRD4AXLFLT3BTK | |
| SCHEMBL29576898 | 0.83 | HTR3A (0.68) | MAP4K1HTR3AHRH4PDE10AEGFR | |
| SCHEMBL29575636 | 0.81 | MAP4K1 (0.53) | MAP4K1BRD4HTR3AHRH4RPS6KA3 | |
| SCHEMBL27174693 | 0.81 | MAP4K1 (0.73) | MAP4K1HTR3AHRH4EGFRALK | |
| SCHEMBL29368254 | 0.80 | MAP4K1 (0.60) | MAP4K1BRD4HTR3AHRH4EGFR | |
| SCHEMBL29576116 | 0.80 | MAP4K1 (0.54) | MAP4K1HTR3AHRH4RPS6KA3EGFR | |
| SCHEMBL29576049 | 0.80 | HTR3A (0.50) | MAP4K1BRD4HTR3AHRH4PDE10A | |
| SCHEMBL29576526 | 0.79 | WEE1 (0.56) | MAP4K1HTR3AHRH4PDE10AEGFR | |
| SCHEMBL29576163 | 0.78 | TNK2 (0.58) | MAP4K1BRD4HTR3AHRH4AXL | |
| SCHEMBL29576362 | 0.76 | HTR3A (0.51) | MAP4K1BRD4HTR3AHRH4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP4K1 16/4885BRD4 474/4885HTR3A 1522/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885BRD4 474/4885HTR3A 1522/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885BRD4 474/4885HTR3A 1522/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP4K1 16/4885BRD4 474/4885HTR3A 1522/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP4K1 16/4885BRD4 474/4885HTR3A 1522/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MAP4K1 25/4885BRD4 1922/4885HTR3A 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.